Indications and Process for PGT-A Screening in Thailand for Chromosomal Abnormalities via Third-Generation IVF
AI Summary
⚕️ AI Summary
The core indications for undergoing IVF in Thailand for chromosomal abnormalities are: One or both partners are carriers of balanced translocation, Robertsonian translocation, or inversion, or have a history of recurrent miscarriage due to aneuploidy, or increased risk of aneuploidy in aged oocytes. Thailand uses third-generation IVF (PGT-A/PGT-SR) to screen embryos for chromosomal copy number variations and select euploid embryos for transfer. Suitable conditions: The female has adequate ovarian reserve (AMH ≥1.0 ng/mL, antral follicle count ≥6) to obtain sufficient oocytes; the type of chromosomal abnormality is confirmed through genetic counseling to be detectable by PGT technology. Unsuitable conditions: The female has severely diminished ovarian function (AMH <0.5), making it impossible to obtain blastocysts for biopsy; or the chromosomal abnormality is a rare single-gene disorder combined with structural abnormalities requiring custom probes. The specific process includes: domestic genetic counseling + karyotype analysis → IVF cycle in Thailand → blastocyst culture → embryo biopsy → PGT-A/PGT-SR testing → frozen embryo transfer. The cycle takes approximately 2.5 to 4 months, with a total cost of about 140,000 to 220,000 RMB.
Reproductive Specialist Perspective Clinical Decision Pathway
Whether a carrier of a chromosomal abnormality is suitable for IVF in Thailand depends on the type of abnormality, ovarian reserve, genetic risk, and the compatibility of PGT technology. Not all chromosomal issues can be resolved by third-generation IVF in Thailand, and not all patients need to go abroad. The following breaks down the indications, process, and key points from the perspective of clinical decision-making in reproductive medicine.
1. Direct Answer: When is it Suitable and When is it Not
Main types of chromosomal abnormalities suitable for IVF in Thailand:
- Balanced translocation / Robertsonian translocation carriers — The proportion of normal/balanced embryos produced is low (about 1/9 to 1/18), and PGT-SR can screen for euploid embryos.
- Chromosomal inversion (especially pericentric inversion of chromosome 9) — If there is recurrent miscarriage or poor sperm quality, PGT can reduce the miscarriage rate.
- Recurrent aneuploidy — For example, advanced maternal age (≥38 years) leading to increased aneuploidy rates in embryos; PGT-A improves transfer efficiency.
- Sex chromosome abnormalities (e.g., 47,XXY, 45,X mosaicism) — Requires combined genetic counseling to assess reproductive risks.
Unsuitable or cautious situations:
- Severely diminished ovarian reserve (AMH <0.5 ng/mL, antral follicle count <4) — Difficulty in obtaining sufficient blastocysts for biopsy.
- Rare complex rearrangements of chromosomal abnormalities (e.g., three-way translocation, insertion translocation) — Standard PGT probes may not cover them; a customized plan is needed.
- Both partners are carriers of the same type of thalassemia (requiring simultaneous PGT-M) — Some laboratories in Thailand can perform PGT-M+PGT-A simultaneously; the platform's capability must be confirmed in advance.
- Untreated uterine factors (e.g., endometrial adhesions, fibroids affecting implantation) — Hysteroscopic evaluation should be performed first before considering embryo screening.
Key points for physician assessment: First, review the karyotype report to identify the type of abnormality; second, assess the female's AMH, FSH, and antral follicle count to evaluate oocyte retrieval potential; finally, confirm whether the Thai laboratory has the corresponding PGT platform (aCGH or NGS). Only proceed with the cycle when all three aspects match.
2. Why Chromosomal Abnormalities Require PGT Intervention
Carriers of structural chromosomal abnormalities (e.g., translocations) produce a large number of unbalanced gametes during meiosis. Taking balanced translocation as an example, theoretically only 1/18 of gametes are completely normal, 1/18 are balanced translocation carriers, and the remaining 16/18 are unbalanced, leading to embryo implantation failure, early miscarriage, or birth defects.
In natural conception, the probability of recurrent miscarriage in balanced translocation carriers is as high as 70% to 90%. Third-generation IVF in Thailand, through blastocyst trophectoderm biopsy and full chromosome screening, directly selects euploid embryos for transfer, reducing the miscarriage rate to a level similar to the general population (10% to 15%).
3. Physician's Perspective: PGT Technology Platforms and Selection Logic in Thailand
Mainstream reproductive centers in Thailand use aCGH (array Comparative Genomic Hybridization) or NGS (Next-Generation Sequencing) platforms for PGT-A/PGT-SR. Both can detect chromosomal copy number variations ≥5Mb, with high detection rates for translocations, inversions, and aneuploidies.
| Platform | Advantages | Limitations |
|---|---|---|
| aCGH | High resolution (~1Mb), good reproducibility, suitable for structural abnormalities | Requires completion within 24 hours; moderate cost |
| NGS | High throughput, can simultaneously detect 24 chromosomes + mitochondrial DNA content | High complexity of data analysis, requires professional bioinformatics team |
Differences between hospitals: Several top laboratories in Thailand (such as BNH, Jetanin, ART, BIC) have NGS-PGT capabilities, but there are differences in the embryo biopsy window, culture system, and genetic counseling process. When choosing, it is necessary to confirm whether the laboratory has PGT-SR (Structural Rearrangement) qualifications, not just PGT-A.
4. The Most Easily Overlooked Detail: Genetic Counseling and Probe Design
For balanced translocation carriers undergoing PGT-SR, it is necessary to know the breakpoint location. Some laboratories use "universal probes" that can cover common translocations, but if the breakpoint is in a gene-dense region or a rare region, custom probes may be required, which adds 2 to 4 weeks of preparation time and additional costs (approximately 15,000 to 30,000 Thai Baht).
Consequences of overlooking this detail: Some patients are only informed after completing ovarian stimulation in Thailand that custom probes are needed. The embryos cannot be tested immediately after biopsy and must be frozen and wait, extending the cycle by 1 to 2 months.
5. Specific Process and Timeline
From domestic preparation to transfer, the complete cycle takes approximately 3 to 4 months (excluding preliminary examinations).
- Domestic Phase (1 to 1.5 months): Karyotype analysis for both partners, genetic counseling, carrier screening (if needed), AMH/hormone profile/semen analysis, infectious disease screening, passport renewal.
- Ovarian Stimulation in Thailand (12 to 15 days): Arrive on day 2 of menstruation, ultrasound + blood hormone monitoring, stimulation for about 10 to 13 days, oocyte retrieval 36 hours after trigger shot.
- Blastocyst Culture + Biopsy (5 to 7 days): Culture to day 5/6 blastocyst after retrieval, trophectoderm biopsy, vitrification.
- PGT Testing (2 to 4 weeks): Sample sent for testing, waiting for chromosome report.
- Frozen Embryo Transfer (1 menstrual cycle): Based on endometrial preparation protocol (natural cycle or hormone replacement cycle), transfer a single euploid blastocyst.
Time reminder: It usually takes 14 to 21 days from biopsy to report. It may be slightly faster with the aCGH platform (10 to 14 days). It is recommended to reserve a total time window of at least 3 months.
6. Cost Influencing Factors
| Item | Cost Range (RMB) |
|---|---|
| Domestic genetic counseling + karyotype | 2,000 ~ 6,000 |
| IVF cycle in Thailand (stimulation + retrieval + culture) | 60,000 ~ 100,000 |
| PGT-A/SR testing (per embryo) | 12,000 ~ 18,000 |
| Custom probe (if needed) | 5,000 ~ 12,000 |
| Frozen embryo transfer cycle | 20,000 ~ 35,000 |
| Total cost (median) | 140,000 ~ 220,000 |
The cost difference mainly comes from: dosage of stimulation medication (individual response), number of embryos biopsied, whether custom probes are needed, and endometrial preparation method for the transfer cycle. The overall cost of IVF in Thailand is 40% to 50% lower than in the United States, but 20% to 30% higher than in domestic private institutions.
7. Frequently Asked Questions (Practitioner Observations)
Q1: What is the success rate of IVF in Thailand for chromosomal abnormalities?
A: The live birth rate per single transfer for carriers of chromosomal abnormalities using third-generation IVF in Thailand is approximately 40% to 55% (based on euploid embryo transfer), and the cumulative live birth rate (1 to 2 oocyte retrievals) can reach 65% to 75%. However, the "success rate" is highly dependent on the female's age and number of oocytes retrieved. For those under 38 years old, with AMH >1.5, and ≥10 oocytes retrieved, the euploidy rate is higher.
Q2: Can PGT-SR in Thailand completely prevent the inheritance of chromosomal problems?
A: PGT-SR can screen for embryos with normal chromosome copy number (including completely normal and balanced carriers), but it cannot distinguish between balanced carriers and completely normal embryos. If a balanced carrier embryo is chosen for transfer, the offspring will still be a carrier, but without pathogenic risk. A few laboratories can distinguish through breakpoint analysis, but this requires additional custom probes.
Q3: What preparation is needed before going to Thailand for patients with chromosomal abnormalities?
A: Must prepare: karyotype reports for both partners (preferably within the last 3 months), genetic counseling records, female AMH + antral follicle count, semen analysis, infectious disease screening (HIV, Hepatitis B, Hepatitis C, Syphilis), passport (valid for ≥6 months). If there are previous chromosome analysis reports from miscarriage tissue, bring them along.
Q4: How many embryos can be transferred at once in IVF in Thailand?
A: Thai law limits the number of embryos transferred to ≤2. However, for patients with chromosomal abnormalities who have undergone PGT screening, single blastocyst transfer is usually recommended to reduce the risk of multiple pregnancies. Multiple pregnancies significantly increase the probability of miscarriage, preterm birth, and pregnancy complications.
8. Differences by Age Group
≤35 years: Carriers of chromosomal abnormalities usually have good oocyte retrieval numbers, with euploidy rates around 45% to 60%. The live birth rate per single transfer after PGT-SR can reach 55% to 65%.
36 to 39 years: Ovarian response begins to decline, oocyte retrieval numbers decrease, and euploidy rates drop to 30% to 45%. Two oocyte retrievals may be needed to accumulate embryos.
≥40 years: Aneuploidy rates increase significantly (≥60%). Even with PGT, the number of euploid embryos is very limited. For those with AMH <0.8, the benefit of IVF in Thailand is significantly reduced, and clinically, it is more inclined to recommend egg donation or a domestic short protocol + PGT.
9. Special Case Management: Mosaicism and Low-Level Translocation
Some patients have a mosaic karyotype (e.g., 45,X/46,XX), or the translocation breakpoint is in a heterochromatic region. In such cases, PGT-SR may not be able to make an accurate judgment. Management approaches: ① Perform additional FISH verification; ② Use SNP-array platform to increase resolution; ③ Combine with genetic counseling to assess actual genetic risk. Some laboratories in Thailand have limited experience with mosaic detection; it is recommended to send the karyotype report to the laboratory in advance to confirm feasibility.
10. Practitioner Observations: Why Some Patients Are Not Suitable for Going Abroad
The most common unsuitable situation encountered in consultations: AMH <0.4 and age ≥40 years. For such patients, even if they go to Thailand, they may retrieve only 1 to 3 oocytes, the probability of forming blastocysts is very low, and there may be no euploid embryos available after PGT. The combined cost of round-trip airfare, accommodation, and medical expenses exceeds 150,000 RMB, with high economic and emotional costs. It is more suitable to first undergo 1 to 2 short protocol cycles domestically to accumulate embryos, or consider egg/embryo donation.
Another easily overlooked factor: the compatibility between the type of chromosomal abnormality and PGT probes. For example, some rare complex translocations (involving more than 3 chromosomes) may not be accurately detected by standard NGS panels in Thailand. It is recommended to send the karyotype report to the laboratory's geneticist for pre-review before departure to avoid being unable to test upon arrival.
⚠️ Doctor's Advice
Before choosing third-generation IVF in Thailand for chromosomal abnormalities, it is essential to complete formal genetic counseling (at a genetics department or reproductive center in a top-tier domestic hospital) to clarify the type of abnormality, genetic probability, and PGT feasibility. Do not fly directly to Thailand based solely on online information. The quality of laboratories in Thailand varies. Choosing a center with PGT-SR qualification certification and a team of geneticists is more reliable. If ovarian reserve is adequate, the abnormality type is clear, and financial conditions allow, third-generation IVF in Thailand is indeed an effective technological pathway to reduce miscarriage rates and birth defects.
Chromosomal Abnormalities Third-Generation IVF Thailand PGT-SR Balanced Translocation Robertsonian Translocation Genetic Counseling Embryo Biopsy Aneuploidy
This article is written by the reproductive medicine editorial team based on clinical consensus from 2024-2025 and does not constitute medical advice. Please refer to the evaluation by the reproductive center physician for specific diagnosis and treatment plans.
